Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) is set to release its earnings data after the market closes on Wednesday, November 1st. Analysts expect Tetraphase Pharmaceuticals to post earnings of ($0.63) per share for the quarter.

Tetraphase Pharmaceuticals (NASDAQ:TTPH) last released its quarterly earnings results on Wednesday, August 2nd. The biopharmaceutical company reported ($0.83) EPS for the quarter, missing analysts’ consensus estimates of ($0.76) by ($0.07). The firm had revenue of $1.59 million for the quarter, compared to analysts’ expectations of $1.54 million. Tetraphase Pharmaceuticals had a negative net margin of 2,092.20% and a negative return on equity of 79.79%. The firm’s revenue for the quarter was up 28.2% on a year-over-year basis. During the same quarter last year, the firm earned ($0.47) earnings per share. On average, analysts expect Tetraphase Pharmaceuticals to post $-2.91 EPS for the current fiscal year and $-2.05 EPS for the next fiscal year.

Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) opened at 6.31 on Wednesday. The stock’s 50 day moving average is $6.87 and its 200-day moving average is $7.12. Tetraphase Pharmaceuticals, Inc. has a 52-week low of $3.11 and a 52-week high of $9.93. The stock’s market capitalization is $322.14 million.

TRADEMARK VIOLATION NOTICE: This story was first published by American Banking News and is the sole property of of American Banking News. If you are viewing this story on another site, it was illegally stolen and reposted in violation of U.S. and international copyright & trademark laws. The original version of this story can be read at https://www.americanbankingnews.com/2017/10/25/tetraphase-pharmaceuticals-inc-ttph-set-to-announce-earnings-on-wednesday.html.

TTPH has been the topic of several recent analyst reports. Piper Jaffray Companies initiated coverage on shares of Tetraphase Pharmaceuticals in a research report on Monday, August 28th. They set an “overweight” rating and a $14.00 price objective on the stock. Zacks Investment Research upgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.75 price objective on the stock in a research report on Saturday, September 23rd. Stifel Nicolaus restated a “buy” rating and set a $13.00 price objective on shares of Tetraphase Pharmaceuticals in a research report on Tuesday, September 12th. ValuEngine downgraded shares of Tetraphase Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, September 1st. Finally, Needham & Company LLC restated a “hold” rating on shares of Tetraphase Pharmaceuticals in a research report on Sunday, September 17th. Two investment analysts have rated the stock with a sell rating, three have issued a hold rating and four have issued a buy rating to the stock. The company has an average rating of “Hold” and a consensus target price of $12.96.

In related news, insider Jacques Dumas sold 17,500 shares of the firm’s stock in a transaction on Tuesday, August 22nd. The shares were sold at an average price of $6.00, for a total transaction of $105,000.00. Following the completion of the transaction, the insider now directly owns 17,500 shares of the company’s stock, valued at $105,000. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 5.50% of the company’s stock.

Tetraphase Pharmaceuticals Company Profile

Tetraphase Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company uses its chemistry technology to create antibiotics for multidrug-resistant infections. The Company is developing its lead product candidate, eravacycline, a fully synthetic tetracycline derivative, as a spectrum intravenous (IV) and oral antibiotic for use as a first-line empiric monotherapy for the treatment of multidrug-resistant infections, including multidrug-resistant gram-negative infections.

Earnings History for Tetraphase Pharmaceuticals (NASDAQ:TTPH)

Receive News & Ratings for Tetraphase Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tetraphase Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.